AgingResearch.NewsJoin free

Doxycycline

InterventionApproved 1967

3 papers3 findings

PubChem 54671203ChEBI 50845MeSH D004318

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 3 independent labs in 2 countries
  • 0 on aging of 170 trials, 36 with no results posted
  • Funders: National Institutes of Health and 1 more
  • Humans1
  • Model organisms1
  • Cells1

Outcomes

2

Working memory

downin mice1

1 study

  1. Doxycycline impairs working memory in mice.

    “both LPS and DOXY independently impaired spatial and non-spatial working memory, locomotor activity, social interaction, and recognition memory, with their interactive treatment exacerbating these deficits significantly”

    Animalsin aging mice

    Lipopolysaccharide-induced Neuroimmune Alteration and Memory Decline in Aging Mice: The Role of Augmented Cellular Senescence

    Neurotoxicity research30 Mar 2026

Integrated stress response

upin cells1

1 study

  1. Doxycycline activates integrated stress response in cells.

    “Mitochondrial-targeting tetracyclines (MitoTets), exemplified by doxycycline, inhibit the mitochondrial ribosome and attenuate cytosolic translation through activation of the Integrated Stress Response (ISR)”

    Cells

    Atypical tetracyclines promote longevity and ferroptotic neuroprotection via translation attenuation

    bioRxiv : the preprint server for biology11 Jan 2026Preprint

More on Integrated stress response

Associations

1

Alzheimer's disease

downin humans1RR 0.92

1 study

  1. Doxycycline lowers the risk of Alzheimer's disease in humans (RR = 0.92, 95% CI 0.87-0.96, p = 0.002).

    “doxycycline prescription was associated with a lowered risk of developing AD compared to patients prescribed Anatomical Therapeutic Chemical (ATC) codes anti‐infectives (risk ratio (RR) = 0.92, adjusted 95% confidence interval (CI) 0.87‐0.96, p ‐value = 0.002)”

    Humans3-year

    Traumatic Brain Injury‐associated gene network‐based prediction and population‐based validation identifies doxycycline as a repurposable medicine for Alzheimer’s Disease

    AAIC 2025 abstract25 Dec 2025

More on Alzheimer's disease

Trials

0 on aging of 170

Approved

All 15

  • FDA Monodox

    29 Dec 1989Fever, Infections, Q Fever, Relapsing Fever, Rocky Mountain Spotted Fever, Urethritis, conjunctivitis

  • FDA Atridox

    3 Sep 1998Discontinued

  • FDA Periostat

    30 Sep 1998Discontinued

  • FDA Periostat

    2 Feb 2001Discontinued

  • FDA Doryx MPC, Doryx

    6 May 2005Anthrax, Bacterial Infections, Fever, Gonorrhea, Infections, Q Fever, Rocky Mountain Spotted Fever, Urethritis, Sexually Transmitted Infections, malaria, severe acne

  • FDA Oracea

    26 May 2006Rosacea, lesions

  • FDA Acticlate

    25 Jul 2014Anthrax, Bacterial Infections, Fever, Gonorrhea, Infections, Q Fever, Rocky Mountain Spotted Fever, Urethritis, Sexually Transmitted Infections, malaria, severe acne

  • FDA Acticlate CAP

    26 Apr 2016DiscontinuedAnthrax, Bacterial Infections, Fever, Gonorrhea, Infections, Q Fever, Rocky Mountain Spotted Fever, Urethritis, Sexually Transmitted Infections, malaria, severe acne

  • FDA Lymepak

    15 Jun 2018Discontinued

Repurposing

40 of 69

In trials

  • Acne vulgaris

    Phase 4Results posted14 trials

  • Sexually transmitted disease

    Phase 4Results posted8 trials

  • Chlamydia Infections

    Phase 4Results posted4 trials

  • Syphilis

    Phase 4Results posted4 trials

  • Homosexuality

    Phase 4Results posted2 trials

  • Rabies

    Phase 4Results posted1 trial

All 23

  • Lyme disease

    Phase 3Completed2 trials

  • Malignant pleural effusion

    Phase 3Completed2 trials

  • Mycosis Fungoides

    Phase 3Status unknown2 trials

  • Nasal Polyps

    Phase 3Completed2 trials

  • Amyloid plaque

    Phase 3Completed1 trial

  • Graves Ophthalmopathy

    Phase 2/3Status unknown3 trials

  • Amyloidosis, Hereditary, Transthyretin-Related

    Phase 2Completed3 trials

  • Breast neoplasm

    Phase 2Terminated2 trials

  • Hereditary Eye Diseases

    Phase 2Status unknown2 trials

  • Lymphoma, T-Cell, Cutaneous

    Phase 2Terminated2 trials

  • Mansonelliasis

    Phase 2Completed2 trials

  • Lymphoma, large b-cell, diffuse

    Phase 2Terminated1 trial

  • Waldenström macroglobulinemia

    Phase 2Terminated1 trial

  • Wounds and injuries

    Phase 2Results posted1 trial

  • Fasting

    Phase 1Completed3 trials

  • Lecithin Cholesterol Acyltransferase Deficiency

    Phase 1Completed2 trials

  • Chronic renal insufficiency

    Phase 1Completed1 trial

Readouts due

Stopped

  • NCT01030666TerminatedPeriodontitis

    shelf life of investigational drug ran out before 90 patients could be included

  • NCT02874430TerminatedBreast neoplasm

    study closed early due to slow accrual

  • NCT02341209TerminatedLymphoma, T-Cell, Cutaneous

    Low enrollment

  • NCT02086591Terminatednon-Hodgkin lymphoma

    Lack of accrual

  • NCT01935622TerminatedSystolic heart failure

    End of funding

  • NCT01590082TerminatedMelanoma

    Accrual slow due to alternate trials and treatment options.

All 7

  • NCT05977868Terminated

    DSMB recommendation based on safety benefit in Experimental (oral) arm

Trial sponsors

Latest

Nov 2025: 0Dec 2025: 2Jan 2026: 1Feb 2026: 1Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 29 in 12 months
bioRxiv

A protein promoted hair cell regeneration in newborn mice

Genetically modified newborn mice produced extra TRIM71, a protein that binds RNA, which promoted spontaneous regrowth of sound-detecting cells in the inner ear.Genetically modified newborn mice produced extra TRIM71, a protein that binds RNA, which promoted spontaneous regrowth of sound-detecting cells in the inner ear.

Preprint: experiments in miceEar
Paper
Communications Biology

Three-protein combination eased chronic liver disease in rats

In experiments in male Wistar rats, intermittently producing three gene-regulating proteins reduced chronic liver injury and scarring and increased survival.In experiments in male Wistar rats, intermittently producing three gene-regulating proteins reduced chronic liver injury and scarring and increased survival.

Experiments in ratsInterventions
Paper

Related